Cannabis and schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Rathbone, John ^a   Variend, Hannele ^b   Mehta, Hetal ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Becklin Centre   (United Kingdom)

^c LANCASHIRE CARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BLOCKING AGENT; CANNABINOID; CANNABIS; DRONABINOL; PLACEBO;

AUSTRALIA; BECK DEPRESSION INVENTORY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG WITHDRAWAL; EFFECT SIZE; GERMANY; HOSPITALIZATION; HUMAN; IRELAND; ITALY; MENTAL HEALTH; NEGATIVE SYNDROME; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SOCIAL INTERACTION; SWEDEN; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 55049128610     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004837.pub2     Document Type: Review

References (73)

1. Edwards 2006 {published data only} Edwards J. Early psychosis service developments: becoming real. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:56. [: KA03]
2. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, McGorry PD. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica 2006;114(2):109-17. [MEDLINE: 16836598]
3. Edwards J, Elkins Ks, Hinton Mf, Harrigan Sm, Donovan Kd, Athanasopoulos O. Randomized controlled trial of a cannabis-focused intervention versus psychoeducation for young people continuing to use cannabis in the 12 months following entry to treatment for first-episode psychosis. Schizophrenia Research 2004;70(1):61. [: ISI:000224551100164]
4. Meltzer 2004 {published data only} Arvanitis L, Bauer D, Rein W. Results of the metatrial project: efficacy and tolerability of four novel compounds in schizophrenia and schizoaffective disorder. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S188. [: P.4.E.039]
5. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry 2004;161(6):975-84. [MEDLINE: 15169685; : EMBASE 2004245661]
6. Rein W, Arvanitis L. Antipsychotic effect of four different compounds - results of the metatrial. Journal of the European College of Neuropsychopharmacology 2003;13(4):S95. [: S.01.01]
7. D'Souza 2005 {published data only} D'Souza DC. Pharmacological studies with delta-9-thc in schizophrenic patients versus controls. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S47. [: S.49.3]
8. D'Souza DC, Abi-Saab W, Madonick S, Wray Y, Forselius K, macDougall L, Brush L, Cassello K, Krystal J. Cannabinoids and psychosis: evidence from studies with IVTHC in schizophrenic patients and controls. Schizophrenia Research 2000;41(1):33. [MEDLINE: 97202599]
9. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005;57(6):594-608. [MEDLINE: 15780846; : EMBASE 2005138690]
10. D'Souza DC, Gil R, Zuzarte E, Zimmerman L, Abi-Saab D, Damon D, White J, Sernyak M, Krystal J. Tetrahydrocannabinol effects in schizophrenic subjects & healthy controls. Schizophrenia Research 1997;24(1,2):213. [MEDLINE: 97202599]
11. D'Souza DCyril, Abi-Saab Walid, Belger Aysenil, Adams Steve, Madonick Steve, Larvey Kristine, Cassello Karyn, Sernyak Michael, Krystal John. Cannabinoid sensitivity in schizophrenia: evidence from a study with intravenous tetrahydrocannabinol in schizophrenics and controls. 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. 1998. [: APA2006L1_4102]
12. D'Souza DD, Abi-Saab W, Madonic S, Belger A, Larvey K, Cassello K, Forselius K, Sernyak M, Krystal. Cannabinoids and psychosis: evidence from studies with IV THC in schizophrenics and controls. Schizophrenia Research 1999;1,2 & 3:104. [MEDLINE: 97202599]
13. Leweke 2000 {published data only} Leweke M, et al.Cannabidiol versus amisulpiride for schizophrenia. Stanley Foundation Research Programs 2000.
14. Leweke 2004 {published data only} Leweke FM. A 31-day, double-blind, randomized, placebo-controlled cross-over study of cannabidiol as monotherapy in 16 patients with schizophrenia. Stanley Foundation Research Programs 2004. [: 05T-678]
15. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
16. Andreasen 1983 Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1983;39:784-8.
17. Andreasson 1987 Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987;2:1483-6.
18. Arseneault 2002 Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-213.
19. Ashton 2001 Ashton CH. Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry 2001;178:101-6.
20. Beck 1961 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:53-63.
21. Berridge 2004 Berridge V. Cannabis Britannica: Empire, trade and prohibition. English Historical Review 2004;483:1075 11075.
22. Birchwood 1992 Birchwood M, Smith J, Cochrane R. Specific and non-specific effects of educational intervention for families living with schizophrenia. A comparison of three methods.. The British Journal of Psychiatry 1992;160:806-14.
23. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
24. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
25. Carney 1984 Carney M, Bacelle, L, Robinson B. Psychosis after cannabis use. BMJ 1984;288:1047.
26. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
27. Chopra 1974 Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Archives of General Psychiatry 1974;30:24-7.
28. Davison 1972 Davison K, Wilson H. Psychosis Associated with Cannabis Smoking. Addiction 1972;67(3):225-28.
29. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
30. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
31. Dixon 1990 Dixon L, Haas G, Wedien PJ, Sweeney J, Frances AJ. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophrenia Bulletin 1990;16:69-79.
32. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
33. Egger 1997 Egger M, Davey G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
34. EMCDDA 2004 An overview of drug potency in Europe. European Monitoring Centre for Drugs and Drug Addiction.
35. Farrell 1998 Farrell M, Howes C, Taylor C. Substance misuse of psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addictive Behavior 1998;23:908-18.
36. Gaoni 1964 Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 1964;86:1646-7.
37. Goldman 1992 Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Pschiatry 1992;149:1148-56.
38. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
39. Hall 1999 Hall W, Johnston L, Donnelly N. The Health Effects of Cannabis. 1st Edition. Toronto: Toronto:Additction Research Foundation, 1999.
40. Hides 2006 Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 2006;189:137-43.
41. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
42. Higgins 2006 Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: Higgins JPT, Green S editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2006.
43. Isbell 1967 Isbell H, Gorodetsky CW, Jasinski D, Claussen U, Spulak F, Korte F. Effects of 9-trans-tetrahydrocannabinol inman. Psychophormacologia 1967;11:184.
44. Jablensky 1992 Jablensky A, Sartorius N, Ernberg G, Anker, M. Schizophrenia: manifestations, incidence and course in different cultures: A World Health Organization ten-country study. Psychological Medicine 1992;Suppl 20:97.
45. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
46. Kay 1986 Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
47. Kouri 1999 Kouri EM, Harrison G, Pope G Jnr. Changes in aggressive behavior during withdrawal from long term marijuana use. Psychopharmacology 1999;143:302-8.
48. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
49. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
50. Leweke 1999 Leweke FM, Guiffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10:1665-69.
51. Linszman 1994 Linszman DH, Dingemans PM, Lenoir ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Archives of General Adult Psychiatry 1994;51:273-9.
52. Lishman 1998 Lishman WA. Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. 3rd Edition. Oxford: Blackwell, 1998.
53. Littlewood 1988 Littlewood R. Ideology, Camouflage or Contingency? Racism in British Psychiatry. Transcultural Psychiatry 1988;30(3):243-90.
54. Marshall 2000 Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
55. McGovern 1987 McGovern D, Cope R. First admission rates of first and second generation Afro-Caribbeans. Journal of Social Distress and the Homeless 1987;22:139-48.
56. Moher 2001 Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
57. Negrete 1986 Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine 1986;16:515-20.
58. Nunez 2002 Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica 2002;105:173-8.
59. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
60. Regier 1990 Regier DA, Farmer ME, Rae DS. Co-morbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association 1990;264:2511-8.
61. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
62. Smith 1994 Smith J, Hucker S. Schizophrenia and substance abuse. British Journal of Psychiatry 1994;165:13-21.
63. Stephens 1993 Stephens RS, Roffman RA, Simpson EE. Adult marijuana users seeking treatment. Journal of Consulting and Clinical Psychology 1993;62:1100-4.
64. Talbot 1969 Talbot JA, Teague JW. Marihuana, Psychosis: Acute Toxic Psychosis Associated With the Use of Cannabis Derivatives. Journal of the American Medical Association 1969;210:299-302.
65. Tanda 1997 Tanda G, Pontiere FE, DiChiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-50.
66. Thomas 1996 Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 1996;42:201-7.
67. Tunving 1985 Tunving K. Psychiatric effects of cannabis use. Acta Psychiatrica Scandinavica 1985;72:209-17.
68. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
69. Van Os 2002 Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 2002;156:319-27.
70. Varma 1972 Varma LP Varma LP. Cannabis psychosis. Indian Journal of Psychiatry 1972;14:241-55.
71. Warnock 1903 Warnock J. Insanity from Hasheesh. Journal of Mental Sciences 1903;49:96-110.
72. Wing 1990 Wing Jk, Barbo T, Brugha T, Burke J, Cooper J, Giel R, Jablenski A, Regier D, Sartorius N. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 1990;47:589-93.
73. Zammit 2002 Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325:1199- 201.